 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
| What is claimed is: 1. A compound having the formula ##STR34## wherein ##STR35## with the proviso ... |
|
| Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents |
| OF THE INVENTION The starting heterocyclic intermediates of the formula ##STR18## are prepared ... |
|
| Oxazolidinedione hypoglycemic agents |
| OF THE INVENTION The compounds of formula I wherein the dotted line represents no bond are ... |
|
| Imidazoline derivatives, salts thereof and their use as pesticides |
| What is claimed is: 1. An imidazoline compound of formula (I): ##STR16## wherein Ar is selected ... |
|
| Pesticidal anilinomethylimidazolines |
| We claim: 1. A method for preventing pests of the Order Acarina from producing viable eggs which ... |
|
| Amidines, preparation process and therapeutical application thereof |
| We claim: 1. Compounds of the formula: ##STR35## in which: R.sub.1 and R.sub.2 represent each a ... |
|
| 3-aryloxy-3-substituted propanamines |
| OF THE INVENTION In the above formula, the term C.sub.1 -C.sub.4 alkyl represents a straight or ... |
|
| Use of .alpha..sub.1C specific compounds to treat benign prostatic hyperlasia |
| OF THE INVENTION The present invention provides a method of treating benign prostatic hyperplasia ... |
|
| Use of .alpha.-1C specific compounds to treat benign prostatic hyperplasia |
| OF THE INVENTION The present invention provides a method of treating benign prostatic hyperplasia ... |
|
| Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| OF THE INVENTION As used throughout this specification and the appended claims, the following ... |
|
|
Device for the preparation of a solution for medical use
| Details |
Inventors: Lascombes, Jean-Jacques;
Assignee:
Primary Examiner: Housel; James C.
Assistant Examiner: Redding; David
Attorney, Agent or Firm: Keck, Mahin & Cate
A device for the extemporaneous and continuous preparation of a solution for dialysis by the dissolution of several substances in powder form in water. The device includes a number of independent cartridges each containing a salt of a substance necessary for the preparation of the dialyzate, such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and sodium bicarbonate. The device includes at least one first conduit communicating with an inlet to the cartridges for introducing water into the cartridges to produce aqueous solutions in said cartridges, at least one second conduit communicating with an outlet from said cartridges for bringing the aqueous solutions to mixing point located upstream from a dialysis circuit, a first measurement device mounted on the second conduit upstream from the mixing point, for measuring the concentration of the aqueous solutions at the outlet of the cartridges, a second measurement device mounted downstream from the dialysis circuit, and at least one flow-rate regulating device for regulating the flow rate of the water to modify the concentration of the aqueous solutions in response to the information provided by the first and second measurement devices. |
|
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS This installation is organized around a device consisting of a set of five cartridges, respectively referenced 1 to 5, arranged in parallel and each of which contains a salt of a substance necessary for the preparation of the dialyzate: sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and sodium bicarbonate.
As specified in the preceding, the internal volume of each cartridge is partially occupied by semipermeable membrane fiber 6 essentially arranged along the longitudinal axis of said cartridges along the length of the first conduits, respectively referenced 11 to 15, of which a first end (indicated by an arrow) is connected to a source of purified water, not represented, which advantageously can be the source used to supply the circuit of water of the dialysis generator.
This water thus penetrates through a second end of said first conduits into each cartridge 1-5 and follows the path defined by the semipermeable membrane fibers.
In a first step, the water thus carried diffuses to the interior of said cartridges by permeating through the membrane fibers, fills the volume of said cartridges, and is mixed with the powdered substances that envelope the fibers.
The water thus loaded with salt then follows the path defined by the membrane fibers, with the concentrated solutions produced in each cartridge being directed to a point where they will be mixed.
For this purpose, at the outlet of cartridges 1-5 are the second conduits, respectively referenced 21 to 25, which are intended to collect the different concentrated solutions produced in order to carry them to a mixing point consisting of third conduit 10, which is connected to the fluid circuits of dialysis generator 100 by conduit 30 provided with pump 31.
One of the main advantages of the device of the invention is that it allows the composition of the dialyzate to be adapted to each clinical case, in a continuous manner during the dialysis session, as a function of the data belonging to each patient obtained in the course of treatment
|
| Related patents |
|
|
Method of producing an artificial kidney perfusion component for bicarbonate dialysis and the artificial kidney perfusion component
After an intensive research undertaken to overcome the above-mentioned disadvantages of the prior arts, the inventor of the present invention discovered that ...
|
|
|
Pharmaceutical preparations containing platinum complexes/phosphonic acid liquid and processes for their use
What is claimed is: 1. A pharmaceutical preparation comprising at least 0.5% by weight of a pharmaceutical vehicle and also comprising a platinum complex or a salt, with ...
|
|
|
Cephalosporin analogues and antimicrobial compositions
What we claim is: 1. The syn isomer of a compound of the formula: ##STR20## wherein R.sup.3 is furyl; A is lower alkoxyiminomethylene; R.sup.2 is carboxy; and ...
|
|
|
Aqueous protein solutions stable to denaturation
What is claimed is: 1. A sterile aqueous solution of a water soluble biologically active protein, which solution has a pH between 6.8 and 8 and additionally has admixed ...
|
|
|
Cyclic analogs of atrial natriuretic peptides
We claim: 1. A peptide compound having natriuretic, diuretic and/or vasodilator activity in mammals, which has the formula: X.sub.1 A.sub.y X.sub.2 -AA.sub.8 -AA.sub.9 -A...
|
|
|
Method for inhibiting blood vessel blockage using octapeptide compositions
In general, the present invention is directed to a method of inhibiting blood vessel blockage in a mammal, e.g., a human, by administering to a patient a therapeutically ...
|
|
|
Novel treatment for acute organic cerebral syndromes (strokes)
I claim: 1. A method for treating individuals suffering from the acute phases of the organic cerebral syndrome due to arterial occlusion which comprises administering to ...
|
|
|
Novel naphthalene derivative
What we claim is: 1. A naphthalene derivative of the formula: ##STR55## wherein Ring A is an unsubstituted benzene ring, a benzene ring having 1 -3 substituent(s) ...
|
|
|
Growth-inhibitory factor obtained from human brain
What is claimed is: 1. A pure protein having a growth-inhibitory activity extracted from the human brain having a molecular weight of about 5000 (according to the SDS-...
|
|
|
Substituted aminopyrimidines as antihypertensives
What is claimed is: 1. A compound having the formula: ##STR16## wherein R.sup.1 is alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, cycloalkyl of 3-7 ...
|
|
|
Vasodialators 
